Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sun Pharmaceutical Industries has reported that FDA has granted tentative approval for the company's abbreviated new drug application for generic Depakote, divalproex sodium delayed release tablets.
Subscribe to our email newsletter
Divalproex sodium delayed release tablets are indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures; as sole and adjunct therapy for patients with simple and complex absence seizures; for the treatment of the manic episodes associated with bipolar disorders, as well as for prophylaxis of migraine headaches.
These generic versions of divalproex sodium delayed release 125mg, 250mg and 500mg (valproic acid activity) tablets are bio-equivalent to Depakote delayed release tablets distributed by Abbott Laboratories.